PA
NAMS icon

PSI Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

PSI Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500
Closed -$10.2K – 465
2025
Q1 		$10.2K Hold
500
– – ﹤0.01% 445
2024
Q4 		$12.8K Hold
500
– – ﹤0.01% 488
2024
Q3 		$8.3K Hold
500
– – ﹤0.01% 569
2024
Q2 		$9.61K Hold
500
– – ﹤0.01% 524
2024
Q1 		$11.8K Buy
+500
New +$10.1K ﹤0.01% 462

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PSI Advisors's NAMS Position: Q2 2025 in Review

PSI Advisors sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 500 shares — an estimated $10.2K sold.

PSI Advisors first reported a position in NAMS in Q1 2024 and held it in 5 quarters. The position peaked at $12.8K in Q4 2024. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

  • PSI Advisors reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
  • PSI Advisors sold 500 NewAmsterdam Pharma shares in Q2 2025, an estimated $10.2K.
  • PSI Advisors first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 5 quarters.
  • PSI Advisors's NewAmsterdam Pharma position peaked at $12.8K in Q4 2024.
  • 131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on PSI Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.